Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Basck Invest Limited holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently associated with this portfolio. The prosecution involves 1 distinct examiner and 1 distinct art unit. This indicates a narrow scope of current activity within the biotechnology sector, where all active legal matters are consolidated into a lone examiner's docket. This concentration is notable within the biotechnology field, where matters are often distributed across a wider range of specialized units.
DONOGHUE, BRITTNEY ERIN is the busiest examiner for Basck Invest Limited. This examiner is currently handling 1 busiest examiner pending office action. With this individual responsible for all active matters, prosecution strategy should be tailored to the specific expectations of this examiner within their assigned art unit. Because there are no other pending actions to balance the workload, the interaction with this single examiner is the primary factor in the company's current patent office trajectory. Success in this technology area will require a deep understanding of the examiner's specific interpretation of pharmaceutical and biotechnological patent standards.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOGHUE, BRITTNEY ERIN | 1 | 59.0% | +47.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17271690 | ANTIGEN-BINDING FRAGMENT AND/OR APTAMER FOR BINDING TO AN EXTRACELLULAR PART OF CD9 AND THERAPEUTIC USES | DONOGHUE, BRITTNEY ERIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17271690 | ANTIGEN-BINDING FRAGMENT AND/OR APTAMER FOR BINDING TO AN EXTRACELLULAR PART OF CD9 AND THERAPEUTIC USES | DONOGHUE, BRITTNEY ERIN | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17271690 | ANTIGEN-BINDING FRAGMENT AND/OR APTAMER FOR BINDING TO AN EXTRACELLULAR PART OF CD9 AND THERAPEUTIC USES | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112 | Final Rejection | — | Pending | Feb 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBasck Invest Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Brittney Erin Donoghue has the most, with 1 of Basck Invest Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.